# Sulfadoxine + pyrimethamine

NOT RECOMMENDED AS AN ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

**EMLc** ATC codes: P01BD51

| | |
|---|---|
| **Indication** | Malaria due to Plasmodium vivax ICD11 code: 1F41 |
| **INN** | Sulfadoxine + pyrimethamine |
| **Medicine type** | Chemical agent |
| **List type** | Core |
| **Additional notes** | Only in combination with artesunate 50 mg |
| **Formulations** | **Oral > Solid:** 500 mg + 25 mg tablet |
| **EML status history** | First added in 1979 (TRS 641)<br>Changed in 1987 (TRS 770)<br>Changed in 2003 (TRS 920)<br>Changed in 2007 (TRS 946)<br>Changed in 2007 (TRS 950)<br>Removed in 2025 (TRS 1064) |
| **Sex** | All |
| **Age** | Also recommended for children |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Wikipedia** | Sulfadoxine + pyrimethamine |
| **DrugBank** | Sulfadoxine, Pyrimethamine |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of sulfadoxine + pyrimethamine tablets from the EML and EMLc for the curative treatment of malaria, given the recommendation to add co-packaged artesunate and sulfadoxine + pyrimethamine to the EML and EMLc for this indication.